Literature DB >> 22476429

Mutation screening of RAD51C in high-risk breast and ovarian cancer families.

Wenping Lu1, Xianshu Wang, Hongsheng Lin, Noralane M Lindor, Fergus J Couch.   

Abstract

Deleterious mutations in the RAD51C gene, which encodes a DNA double-strand break repair protein, have been reported to confer high-penetrance susceptibility to both breast and ovarian cancer. To confirm this we conducted a mutation screen of the RAD51C gene in 192 probands from high-risk breast and/or ovarian cancer families that do not carry BRCA1 or BRCA2 mutations. The nine exons of the RAD51C gene containing protein coding sequence were screened for mutations in genomic DNA from family probands by high-resolution melting analysis and direct DNA sequencing. Four missense variants, p.Ser364Gly, p.Ala126Thr, p.Val169Ala, and p.Thr287Ala were detected in six patients. The p.Ser364Gly variant is a novel variant predicted to have little influence on RAD51C activity. The p.Ala126Thr and p.Val169Ala variants have been reported to have no association with risk of breast cancer in a case-control study. However, p.Thr287Ala disrupts the DNA repair activity of RAD51C, suggesting some influence on risk. Consistent with published results from similar follow-up studies, we suggest that RAD51C mutations are rare events among high-risk breast cancer and breast/ovarian cancer families. Large population-based studies will be needed to reliably assess the prevalence and penetrance of inactivating mutations in the RAD51C susceptibility gene.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22476429      PMCID: PMC3418444          DOI: 10.1007/s10689-012-9523-9

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  26 in total

1.  Complex formation by the human RAD51C and XRCC3 recombination repair proteins.

Authors:  J Y Masson; A Z Stasiak; A Stasiak; F E Benson; S C West
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

2.  Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.

Authors:  Mikko Vuorela; Katri Pylkäs; Jaana M Hartikainen; Karin Sundfeldt; Annika Lindblom; Anna von Wachenfeldt Wäppling; Maria Haanpää; Ulla Puistola; Annika Rosengren; Maarit Anttila; Veli-Matti Kosma; Arto Mannermaa; Robert Winqvist
Journal:  Breast Cancer Res Treat       Date:  2011-07-13       Impact factor: 4.872

3.  RAD51C germline mutations in Chinese women with familial breast cancer.

Authors:  Zhiyuan Pang; Lu Yao; Juan Zhang; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqing Fan; Tie Fan; Benyao Lin; Yuntao Xie
Journal:  Breast Cancer Res Treat       Date:  2011-05-20       Impact factor: 4.872

4.  RAD51C is a susceptibility gene for ovarian cancer.

Authors:  Liisa M Pelttari; Tuomas Heikkinen; Deborah Thompson; Anne Kallioniemi; Johanna Schleutker; Kaija Holli; Carl Blomqvist; Kristiina Aittomäki; Ralf Bützow; Heli Nevanlinna
Journal:  Hum Mol Genet       Date:  2011-05-25       Impact factor: 6.150

5.  ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.

Authors:  A Broeks; J H Urbanus; A N Floore; E C Dahler; J G Klijn; E J Rutgers; P Devilee; N S Russell; F E van Leeuwen; L J van 't Veer
Journal:  Am J Hum Genet       Date:  2000-02       Impact factor: 11.025

Review 6.  A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).

Authors:  Noralane M Lindor; Lucia Guidugli; Xianshu Wang; Maxime P Vallée; Alvaro N A Monteiro; Sean Tavtigian; David E Goldgar; Fergus J Couch
Journal:  Hum Mutat       Date:  2011-11-03       Impact factor: 4.878

7.  Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.

Authors:  Ella R Thompson; Samantha E Boyle; Julie Johnson; Georgina L Ryland; Sarah Sawyer; David Y H Choong; Georgia Chenevix-Trench; Alison H Trainer; Geoffrey J Lindeman; Gillian Mitchell; Paul A James; Ian G Campbell
Journal:  Hum Mutat       Date:  2011-11-04       Impact factor: 4.878

8.  Germline mutations in RAD51D confer susceptibility to ovarian cancer.

Authors:  Chey Loveday; Clare Turnbull; Emma Ramsay; Deborah Hughes; Elise Ruark; Jessica R Frankum; Georgina Bowden; Bolot Kalmyrzaev; Margaret Warren-Perry; Katie Snape; Julian W Adlard; Julian Barwell; Jonathan Berg; Angela F Brady; Carole Brewer; Glen Brice; Cyril Chapman; Jackie Cook; Rosemarie Davidson; Alan Donaldson; Fiona Douglas; Lynn Greenhalgh; Alex Henderson; Louise Izatt; Ajith Kumar; Fiona Lalloo; Zosia Miedzybrodzka; Patrick J Morrison; Joan Paterson; Mary Porteous; Mark T Rogers; Susan Shanley; Lisa Walker; Diana Eccles; D Gareth Evans; Anthony Renwick; Sheila Seal; Christopher J Lord; Alan Ashworth; Jorge S Reis-Filho; Antonis C Antoniou; Nazneen Rahman
Journal:  Nat Genet       Date:  2011-08-07       Impact factor: 38.330

9.  Mutation screening of RAD51C in male breast cancer patients.

Authors:  Valentina Silvestri; Piera Rizzolo; Mario Falchetti; Ines Zanna; Giovanna Masala; Domenico Palli; Laura Ottini
Journal:  Breast Cancer Res       Date:  2011-02-08       Impact factor: 6.466

10.  RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.

Authors:  Jessica Clague; Greg Wilhoite; Aaron Adamson; Adam Bailis; Jeffrey N Weitzel; Susan L Neuhausen
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

View more
  8 in total

1.  Rare Coding Variants Associated with Breast Cancer.

Authors:  Mi-Ryung Han
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.

Authors:  Jill J J Geenen; Sabine C Linn; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

3.  Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.

Authors:  Renaud Sabatier; Elise Lavit; Jessica Moretta; Eric Lambaudie; Tetsuro Noguchi; François Eisinger; Elisabeth Cherau; Magali Provansal; Doriane Livon; Laetitia Rabayrol; Cornel Popovici; Emmanuelle Charaffe-Jauffret; Hagay Sobol; Patrice Viens
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

Review 4.  Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms.

Authors:  Zeinab Safarpour Lima; Mostafa Ghadamzadeh; Farzad Tahmasebi Arashloo; Ghazaleh Amjad; Mohammad Reza Ebadi; Ladan Younesi
Journal:  J Hematol Oncol       Date:  2019-04-11       Impact factor: 17.388

5.  BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.

Authors:  Malwina Suszynska; Magdalena Ratajska; Piotr Kozlowski
Journal:  J Ovarian Res       Date:  2020-05-02       Impact factor: 4.234

6.  Post-transcriptional regulation of Rad51c by miR-222 contributes cellular transformation.

Authors:  Emilio Rojas; Monica Martinez-Pacheco; Maria Alexandra Rodriguez-Sastre; Paulina Ramos-Espinosa; Mahara Valverde
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240

7.  Rare coding variants and breast cancer risk: evaluation of susceptibility Loci identified in genome-wide association studies.

Authors:  Yanfeng Zhang; Jirong Long; Wei Lu; Xiao-Ou Shu; Qiuyin Cai; Ying Zheng; Chun Li; Bingshan Li; Yu-Tang Gao; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-01-27       Impact factor: 4.254

8.  Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients.

Authors:  Liisa M Pelttari; Riikka Nurminen; Alexandra Gylfe; Lauri A Aaltonen; Johanna Schleutker; Heli Nevanlinna
Journal:  BMC Cancer       Date:  2012-11-23       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.